249 related articles for article (PubMed ID: 37486599)
21. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma.
Zhou D; Wang Y; Cheng H; Zhu L; Chen W; Li H; Zhang X; Xia J; Qi Y; Ma S; Zhu F; Yan Z; Qi K; Sang W; Sun H; Li D; Cao J; Li Z; Xu K
J Infect Chemother; 2023 Feb; 29(2):179-185. PubMed ID: 36368473
[TBL] [Abstract][Full Text] [Related]
23. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
24. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
[TBL] [Abstract][Full Text] [Related]
25. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
27. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
[TBL] [Abstract][Full Text] [Related]
28. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
[TBL] [Abstract][Full Text] [Related]
29. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
30. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
31. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
32. Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy.
Ababneh HS; Yee AJ; Raje NS; Martin S; Frigault MJ; Ng AK; Patel CG
Radiother Oncol; 2023 Dec; 189():109933. PubMed ID: 37778534
[TBL] [Abstract][Full Text] [Related]
33. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
34. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Wang Y; Li C; Xia J; Li P; Cao J; Pan B; Tan X; Li H; Qi K; Wang X; Shi M; Jing G; Yan Z; Cheng H; Zhu F; Sun H; Sang W; Li D; Zhang X; Li Z; Zheng J; Liang A; Zhou J; Xu K
Blood Adv; 2021 Dec; 5(23):5290-5299. PubMed ID: 34587230
[TBL] [Abstract][Full Text] [Related]
35. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
[TBL] [Abstract][Full Text] [Related]
36. GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S; Devlin SM; Landa J; Nath K; Diamonte C; Carstens EJ; Russo D; Auclair R; Fitzgerald L; Cadzin B; Wang X; Sikder D; Senechal B; Bermudez VP; Purdon TJ; Hosszu K; McAvoy DP; Farzana T; Mead E; Wilcox JA; Santomasso BD; Shah GL; Shah UA; Korde N; Lesokhin A; Tan CR; Hultcrantz M; Hassoun H; Roshal M; Sen F; Dogan A; Landgren O; Giralt SA; Park JH; Usmani SZ; Rivière I; Brentjens RJ; Smith EL
N Engl J Med; 2022 Sep; 387(13):1196-1206. PubMed ID: 36170501
[TBL] [Abstract][Full Text] [Related]
37. BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Zhao G; Wei R; Feng L; Wu Y; He F; Xiao M; Cheng Z
Cancer Immunol Immunother; 2022 Jan; 71(1):39-44. PubMed ID: 34003300
[TBL] [Abstract][Full Text] [Related]
39. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
40. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
Wat J; Barmettler S
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
